Lubiprostone Approved in Switzerland for Chronic Idiopathic Constipation
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Lubiprostone Approved in Switzerland for Chronic Idiopathic Constipation

NEW YORK -- November 19, 2009 -- The Swiss Agency for Therapeutic Products has granted a marketing authorization for lubiprostone (Amitiza) 24 mcg gel capsules for the long-term treatment of patients with chronic idiopathic constipation.

The approval was based upon an assessment of safety and efficacy data obtained from a comprehensive clinical development program, including results of 2 randomised phase 3 studies in adult patients with chronic idiopathic constipation conducted in the United States.

The pooled data from these trials showed that 60% of patients treated with lubiprostone experienced a spontaneous bowel movement (SBM) within 24 hours of treatment and 80% experienced an SBM within 48 hours of treatment, compared with 35% and 63% of placebo patients, respectively (P < .0001).

In addition, lubiprostone showed improvement in long-term symptom relief of irritable bowel syndrome, with significant improvements in constipation severity, abdominal bloating and abdominal discomfort for up to 12 months.

The most common adverse reactions (incidence >4%) were nausea, diarrhoea, headache, abdominal pain, abdominal distention, and flatulence.

SOURCE: Sucampo Pharmaceuticals

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities